First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer is a phase 1/2 interventional study registered as NCT06934538 by Brenus Pharma, with 90 participants planned, started 2025-06-17 and due to reach its primary completion in 2028-06. Interventions recorded: STC-1010 + IS regimen + SOC therapy.